10x Genomics announced clinical collaborations with Brigham & Women’s Hospital, Dana‑Farber Cancer Institute and the Cancer Research Institute and plans to build a CLIA‑certified lab to support clinical deployment of single‑cell and spatial assays. The company’s move expands beyond research tools into generating clinical evidence and enabling patient testing. 10x also broadened partnerships to streamline data analysis and clinical pipelines, signaling a shift toward services and diagnostic-grade operations. The strategy aims to capture downstream clinical demand for spatial and single‑cell assays, with implications for reimbursement, regulatory compliance and diagnostic market competition.